Annals of Oncology

Annals of Oncology is a premier peer-reviewed medical journal dedicated to the field of oncology, publishing high-impact research that advances the understanding and treatment of cancer. The journal’s scope encompasses all aspects of clinical oncology, with a strong emphasis on translational research, molecular pathology, cancer biology, and therapeutic innovation. Main topics include systemic therapy (chemotherapy, targeted therapy, immunotherapy), precision oncology, clinical trial results, cancer epidemiology, and supportive care. The journal features a range of article types, including original research articles, comprehensive reviews, editorials, and special reports, along with rapid communications and correspondence that facilitate timely discourse on emerging findings. Its target audience includes clinical oncologists, medical researchers, pharmacologists, and healthcare professionals involved in cancer care and drug development. Published by Elsevier on behalf of the European Society for Medical Oncology (ESMO), Annals of Oncology is a hybrid open-access journal, offering authors the option to publish their work open access for broader dissemination. With an extraordinary Impact Factor of 80.400 for 2026, it ranks in the JCR Q1 quartile, consistently placing among the very top journals in oncology globally. This standing underscores its role as a leading source of landmark clinical studies and practice-changing guidelines, making it an essential resource for anyone seeking the most authoritative and current advancements in cancer research and clinical management.